Corbus Pharmaceuticals Presents Additional Data from RESOLVE-1 Study in Systemic SclerosisGlobeNewsWire • 11/09/20
Corbus Pharmaceuticals (CRBP) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 10/29/20
Corbus Pharmaceuticals Announces Presentation of Data from its Phase 2b Study in Cystic Fibrosis at NACFC 2020GlobeNewsWire • 10/23/20
Corbus Pharmaceuticals Announces Three Lenabasum Abstracts to be Presented at ACR Convergence 2020GlobeNewsWire • 10/21/20
Corbus Pharmaceuticals Announces Corporate Restructuring and Pipeline Portfolio UpdatesGlobeNewsWire • 10/08/20
Corbus Pharmaceuticals Announces Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis Did Not Meet Primary EndpointGlobeNewsWire • 10/06/20
Corbus Pharmaceuticals Announces Topline Results from RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic SclerosisGlobeNewsWire • 09/08/20
Corbus Pharmaceuticals Holdings, Inc. (CRBP) CEO Yuval Cohen on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/06/20
Corbus Pharmaceuticals Reports Second Quarter Financial Results and Corporate UpdatesGlobeNewsWire • 08/06/20
Corbus Pharmaceuticals Completes Enrollment in DETERMINE Phase 3 Study of Lenabasum for Treatment of DermatomyositisGlobeNewsWire • 08/05/20
Corbus Pharmaceuticals Strengthens Balance Sheet with up to $121 Million in New CapitalGlobeNewsWire • 07/29/20
After 6 Years Corbus Shareholders Face The Ultimate Milestone: The Imminent Release Of Lenabasum's Phase 3 DataSeeking Alpha • 07/22/20
Corbus Pharmaceuticals Appoints George Golumbeski, Ph.D., to Board of DirectorsGlobeNewsWire • 07/08/20
Corbus Pharmaceuticals Presents Data Demonstrating ACR CRISS Score Reflects Patient-Reported Outcomes at 6th Systemic Sclerosis World E-CongressGlobeNewsWire • 06/29/20
Corbus Pharmaceuticals Reports Last Subject Visit in Phase 2b Study of Lenabasum for Treatment of Cystic FibrosisGlobeNewsWire • 06/22/20
Is the Options Market Predicting a Spike in Corbus Pharmaceuticals (CRBP) Stock?Zacks Investment Research • 06/18/20
Corbus Pharmaceuticals Announces Publication of Phase 2b Cystic Fibrosis Study Patient Demographics and Baseline Disease Characteristics in the Journal of Cystic FibrosisGlobeNewsWire • 06/01/20